镭-223联合多西他赛治疗去势抵抗性前列腺癌骨转移患者:1期剂量递增/随机2a期试验
该研究为1期剂量递增及随机2a期试验,评估镭-223联合多西他赛在骨转移为主的转移性去势抵抗性前列腺癌(mCRPC)中的安全性和疗效。1期确定联合方案推荐2期剂量(RP2D)为镭-223 55 kBq/kg每6周×5次联合多西他赛60 mg/m²每3周×10次,发热性中性粒细胞减少为剂量限制性毒性;2a期联合组较单药组显示更持久的前列腺特异性抗原抑制,探索性疗效数据提示联合组抗肿瘤活性增强。
要点
- 1期确定联合方案RP2D:镭-223 55 kBq/kg每6周×5次联合多西他赛60 mg/m²每3周×10次,发热性中性粒细胞减少为剂量限制性毒性。
- 2a期联合组(36例)与多西他赛单药组(17例)安全性总体相似,但单药组发热性中性粒细胞减少发生率更高(15% vs 0%)。
- 联合组前列腺特异性抗原中位进展时间6.6个月 vs 单药组4.8个月,碱性磷酸酶中位进展时间9个月 vs 7个月。
核心结论
- 镭-223联合多西他赛在RP2D下耐受性良好,探索性疗效数据提示联合组相对多西他赛单药抗肿瘤活性增强。
- 需要开展以临床获益为终点的对照研究。
研究设计与样本
- 1期剂量递增研究确定多西他赛联合镭-223的推荐2期剂量(RP2D)。
- 2a期随机研究按2:1将患者分配至推荐联合方案组或多西他赛75 mg/m²每3周组。
- 入组骨转移为主的mCRPC患者;1期入组20例,2a期随机53例(联合组36例,多西他赛单药组17例)。
- 终点为安全性、疗效及血清和影像生物标志物的治疗相关变化。
主要发现
- 1期确定联合方案RP2D为镭-223 55 kBq/kg每6周×5次联合多西他赛60 mg/m²每3周×10次,发热性中性粒细胞减少为剂量限制性毒性。
- 多西他赛单药组发热性中性粒细胞减少发生率高于联合组(15% vs 0%),其余安全性特征两组相似。
- 联合组前列腺特异性抗原中位进展时间6.6个月 vs 单药组4.8个月。
- 联合组碱性磷酸酶中位进展时间9个月 vs 单药组7个月。
- 联合组对成骨性骨沉积标志物的抑制更持久。
关键数值与推荐
- 联合方案RP2D:镭-223 55 kBq/kg每6周×5次,联合多西他赛60 mg/m²每3周×10次。
- 2a期多西他赛单药组剂量为75 mg/m²每3周。
- 发热性中性粒细胞减少为剂量限制性毒性。
- 联合组前列腺特异性抗原中位进展时间6.6个月 vs 单药组4.8个月;碱性磷酸酶中位进展时间9个月 vs 7个月。
- 多西他赛单药组发热性中性粒细胞减少发生率15% vs 联合组0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要开展以临床获益为终点的对照研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radium 223 dichloride (radium-223) is an alpha particle-emitting bone-directed therapy that prolongs overall survival in men with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Docetaxel is an antimicrotubule cytotoxic agent that improves survival in mCRPC. We investigated whether combining these potentially cross-sensitising agents to dually target tumour and bone would be safe and effective. PATIENTS AND METHODS: Phase 1 was a dose escalation study to define a recommended phase 2 dose (RP2D) of docetaxel and radium-223. In phase 2a, patients were randomised 2:1 to the recommended combination regimen or docetaxel at a dose of 75 mg/m2 every 3 weeks (q3w). Patients with bone-predominant mCRPC were eligible. End-points were safety, efficacy and treatment-related changes in serum and imaging biomarkers. RESULTS: Twenty patients were enrolled in phase 1; 53 patients were randomised in phase 2a: 36 to combination treatment and 17 to docetaxel alone. The RP2D for the combination was radium-223 55 kBq/kg every six weeks × 5 doses, plus docetaxel 60 mg/m2 q3w × 10 doses. Febrile neutropenia was dose limiting. A higher rate of febrile neutropenia was seen in the docetaxel monotherapy arm (15% vs 0%); the safety profile of the treatment groups was otherwise similar. The combination arm had more durable suppression of prostate-specific antigen (median time to progression, 6.6 vs 4.8 months, respectively), alkaline phosphatase (9 vs 7 months) and osteoblastic bone deposition markers. CONCLUSIONS: Radium-223 in combination with docetaxel at the RP2D was well tolerated. Exploratory efficacy data suggested enhanced antitumour activity for the combination relative to docetaxel alone. Comparative studies with end-points of clinical benefit are warranted. ClinicalTrials.gov number: NCT01106352.
引用
- Morris MJ, Loriot Y, Sweeney CJ, et al. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019. PMID: 31082669. doi:10.1016/j.ejca.2019.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。